RaySearch Laboratories develops software solutions for radiation therapy and oncology. The company's core product is RayStation, a dose planning system used by clinics globally to support photon, electron, proton, and other particle therapy platforms. The product portfolio also includes RayCare for treatment information management, RayIntelligence for cloud-based oncology data analysis, RayCommand for treatment control, and DrugLog for quality assurance of injectable medications. RaySearch serves cancer clinics and research institutions worldwide, with a strong position in particle therapy dose planning. The company partners with treatment machine manufacturers and clinical centers to integrate its software with existing and refurbished equipment, including a collaboration with Radiology Oncology Systems to extend the lifespan of linear accelerators. Founded in 2000, RaySearch generates revenue through software licenses, support agreements, hardware sales, and training services.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Software - Application Homepage raysearchlabs.com
Sector Technology IR page raysearchlabs.com
Tags
radiation therapy, dose planning, oncology software, particle therapy, adaptive radiotherapy, medical imaging, treatment control, clinical data analysis, RayStation, RayCare, RayIntelligence, RayCommand, DrugLog, RayAcademy, Radiology Oncology Systems
Press page raysearchlabs.com/media/press-releases

Metrics

Valuation  
Market cap kr 5.921B
Market cap (USD) $ 582.801M
P/E 28.93
PEG 0.26
P/BV 6.01
P/S 4.40
P/OCF 15.30
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 24.5%
ROI 23.1%
ROIC 23.5%
Profit margin 16.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 112.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 85
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 1.344B 1.192B 1.022B 843.648M 641.673M 651.612M 741.584M 627.218M 585.086M 531.468M 397.6M 285.217M 204.47M 182.087M 126.103M 117.728M 83.687M
Net profit 227.8M 203.513M 81.572M 23.778M -47.315M -9.08M 50.411M 78.523M 117.627M 151.408M 70.209M 59.832M -20.842M 19.863M 17.007M 28.895M 30.146M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 227 150 90.3 68 82.7 — 107.2 96.5 171 184.5 122.5 53 — — — — —
Price performance 12m 0.51 0.66 0.33 -0.18 0 — 0.11 -0.44 -0.07 0.51 1.31 — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 157M 171M 247M 240M 255M 240M
↳ YoY growth +8.8% +44.6% -2.7% +6.0% -5.9%
↳ 5y CAGR +8.8%
Other receivables (SEK) — 37.3M 38M 16.4M 18.1M 17.9M 12.4M
Borrowings, current (SEK) — — 70.4M 58.3M — — —
Lease liabilities (SEK) — — 491M 497M 529M 472M 395M
Cash and deposits (SEK) 114M 169M 103M 160M 344M 463M 407M
Intangible assets (SEK) — — — 342,000 116,000 7.01M 5.6M
Right-of-use assets (SEK) — 92.8M 540M 540M 501M 457M 384M
Net debt (borrowings + leases - cash) (SEK) — — 459M 395M — — —
Cash flow detail
Operating cash flow (SEK) — 332M 238M 357M 456M 485M 387M
Purchases of property, plant and equipment (SEK) — -29.7M -52M -43.5M -24.3M -13.3M -28.1M
Purchases of intangible assets (SEK) — -196M -203M -188M 0.00 -7M 0.00
Change in receivables (cash effect) (SEK) — 52.2M 17.1M -66M 31.8M -23.9M -71.4M
Change in payables (cash effect) (SEK) — 79.8M 35.5M 108M 29.6M -1.39M -70.4M
Dividends paid (cash effect) (SEK) — — — — — -68.6M -103M
Interest paid (cash effect) (SEK) — — -6.04M -11.5M — — —
Income taxes paid (cash effect) (SEK) — -28.2M 17.6M -13.8M -16.4M -8.87M -93.1M
Operating cash flow before change in receivables (SEK) — 279M 221M 423M 424M 509M 458M
Free cash flow (OCF - PPE - intangibles) (SEK) — 106M -17.1M 125M 432M 465M 359M
Income detail
Research and development expense (SEK) — 185M 233M 239M 238M 269M 270M
↳ 5y CAGR +7.9%
Total comprehensive income (SEK) — -11.1M -45.1M 28.8M 78.1M 210M 211M
Comprehensive income to owners (SEK) — — — 28.8M 78.1M 210M 211M
Reported — — — — — — —

Operating KPIs — years

KPI Dec 2021 Dec 2022 Dec 2024 Dec 2025
Order intake (USD) 808M 1.22B 1.09B 1.28B
↳ YoY growth +50.8% +17.4%
Reported — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PDF

RaySearchs delårsrapport för tredje kvartalet 2026 kommer att publiceras tisdagen den 3 november kl. 07.30 CET. En webbsänd presentation hålls kl. 11.00 samma dag.

Johan Löf, grundare och vd, samt Nina Grönberg, CFO, kommer att presentera och kommentera rapporten. Presentationen hålls på engelska och följs av en frågestund. Frågor kan också skickas skriftligen till [email protected] .

Följ den webbsända presentationen live på: Q3 2026 presentation

Vänligen försäkra dig om att du är ansluten till presentationen genom att logga in några minuter innan den börjar. Presentationsmaterialet kommer att finnas på RaySearchs webbplats, tillsammans med rapporten och en inspelning av presentationen.

Välkommen!

PDF

RaySearch will publish its report for the third quarter of 2026 on Tuesday, November 3, at 7:30 a.m. CET. A webcast presentation will be held at 11:00 a.m. on the same day.

Johan Löf, founder and CEO, and Nina Grönberg, CFO, will present and comment on the report. The presentation will be held in English, followed by a Q&A session. Questions may also be submitted in writing to [email protected] .

Follow the webcast presentation live at: Q3 2026 presentation

Please make sure you are connected to the presentation by logging in a few minutes before it starts. The presentation materials, along with the report and a recording of the presentation, will be made available on RaySearch’s website.

Welcome!

PDF

RaySearch Laboratories AB (publ) and the International Atomic Energy Agency (IAEA) are proud to announce the signing of an agreement at the 70th IAEA General Conference, bringing RaySearch into the Rays of Hope initiative.

The multi-year partnership aims to strengthen cooperation and expand access to safe, effective and sustainable radiotherapy services, particularly in countries and regions where access to radiotherapy remains limited.

The agreement establishes a framework for collaboration in areas including awareness-raising and research in radiotherapy treatment planning and quality assurance. It also includes the potential provision of software solutions to support selected cancer centers participating in Rays of Hope, including Anchor Centers that serve as regional knowledge and capacity-building hubs.

“Partnerships with industry are helping the IAEA expand access to cancer diagnosis and treatment around the world. Working together, we can bring life-saving cancer services to more people, no matter where they live," says IAEA Director General Rafael Mariano Grossi.

While investments in radiotherapy equipment are critical, advanced software plays an equally important role in ensuring that treatments are delivered safely, accurately and efficiently. Treatment planning systems and oncology information systems enable radiation oncologists and medical physicists to design personalized treatment plans, streamline clinical workflows and support quality assurance, helping healthcare providers make the most of available resources.

Through the collaboration, RaySearch may explore opportunities to support facilities identified by the IAEA with software, application-specific training, and technical expertise. With its vendor-agnostic approach and broad range of cancer care solutions, RaySearch can help strengthen radiotherapy capacity and support high-quality cancer care.

"Cancer is a global challenge, but access to advanced radiotherapy is still far from equal. In many parts of the world, access to radiotherapy remains limited. We are proud to collaborate with the IAEA and contribute our software, expertise and experience to the Rays of Hope initiative. Together, we hope to strengthen radiotherapy capabilities and support healthcare professionals in delivering safe and effective treatments to more patients around the world," says Johan Löf, founder and CEO of RaySearch Laboratories.

Prompts

RaySearch Laboratories (ticker RAY-B), listed in Sweden.

ETFs Holding RaySearch Laboratories

ETF Weight in ETF Shares Market value As of
AVDV 0.07% 815,072 $ 14.391M Nov 16, 2026
DFIS 0.03% 103,205 $ 1.815M Nov 12, 2026
AVDS 0.03% 5,198 $ 91.777K Nov 16, 2026
AVDE 0.01% 96,704 $ 1.707M Nov 16, 2026
AVSD 0.01% 2,266 $ 40.009K Nov 16, 2026
DFSI 0.01% 5,773 $ 101.499K Nov 12, 2026
DFIC 0.01% 56,181 $ 987.758K Nov 12, 2026
DXIV 0.01% 839 $ 14.751K Nov 12, 2026
DFAX 0.00% 16,035 $ 281.923K Nov 12, 2026
DFAI 0.00% 21,917 $ 385.338K Nov 12, 2026